Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.

Key facts

Study ID

NCT00193245

Run by

SCRI Development Innovations, LLC

People needed

80

Starts

2000-11-01

Expected to finish

2009-01-01

Last updated by the study team

2010-06-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be included in this study, you must meet the following criteria:
• Relapsed or Progressive Disease
• Stage IIIB (not candidate for combined modality) or IV
• No more than one prior chemotherapy regimen
• Able to perform activities of daily living without assistance
• Measurable disease outside of radiation port
• Adequate bone marrow, liver and kidney function
• Must understand study and sign informed consent prior to enrollment

You may not qualify if…

• You cannot participate in this study if any of the following apply to you:
• Prior treatment with Topotecan or Docetaxel
• Uncontrolled brain metastases
• Moderate peripheral neuropathy
• Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Where it is running

• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.